NuCana PLC Financials
| NCNA Stock | USD 1.03 0.08 7.21% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.0251 | 0.0239 |
|
| |||||
| Current Ratio | 2.16 | 2.27 |
|
|
The essential information of the day-to-day investment outlook for NuCana PLC includes many different criteria found on its balance sheet. An individual investor should monitor NuCana PLC's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in NuCana PLC.
Net Income |
|
NuCana | Select Account or Indicator |
Please note, the presentation of NuCana PLC's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, NuCana PLC's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of NuCana PLC's management manipulating its earnings.
NuCana PLC Stock Summary
NuCana PLC competes with Zura Bio, ZyVersa Therapeutics, Cidara Therapeutics, Silence Therapeutics, and Applied Therapeutics. NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom. Nucana Plc is traded on NASDAQ Exchange in the United States.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US67022C1062 |
| CUSIP | 67022C106 67022C205 |
| Location | United Kingdom |
| Business Address | 3 Lochside Way, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.nucana.com |
| Phone | 44 13 1357 1111 |
| Currency | USD - US Dollar |
NuCana PLC Key Financial Ratios
| Return On Equity | -1.81 | ||||
| EBITDA | (28.89 M) | ||||
| Net Income | (27.63 M) | ||||
| Cash Per Share | 0.90 X | ||||
| Debt To Equity | 0 % |
NuCana PLC Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 107.8M | 77.5M | 58.3M | 27.8M | 32.0M | 30.4M | |
| Other Current Liab | 5.2M | 9.3M | 13.9M | 8.9M | 10.3M | 5.3M | |
| Net Tangible Assets | 59.6M | 94.5M | 63.1M | 36.1M | 41.6M | 66.3M | |
| Retained Earnings | (110.6M) | (149.7M) | (180.6M) | (207.7M) | (186.9M) | (177.6M) | |
| Accounts Payable | 2.3M | 1.8M | 4.8M | 3.4M | 3.9M | 2.2M | |
| Cash | 87.4M | 60.3M | 41.9M | 17.2M | 19.8M | 18.8M | |
| Other Assets | 46K | 44K | 2.6M | 103K | 118.5K | 112.5K | |
| Net Receivables | 14.5M | 11.3M | 10.3M | 5.8M | 6.7M | 8.2M | |
| Inventory | (1.8M) | (13.2K) | (14.5K) | (11.3K) | (13.1K) | (13.7K) | |
| Other Current Assets | 3.8M | 3.1M | 13.0M | 2.0M | 2.3M | 2.2M | |
| Total Liab | 8.6M | 11.9M | 19.8M | 12.9M | 14.9M | 8.1M | |
| Total Current Assets | 101.8M | 71.6M | 54.9M | 25.0M | 28.8M | 27.3M | |
| Short Term Debt | 556K | 414K | 486K | 206K | 236.9K | 212.3K | |
| Intangible Assets | 4.8M | 2.4M | 2.4M | 2.1M | 2.4M | 2.6M | |
| Common Stock | 2.0M | 2.1M | 2.1M | 2.1M | 1.9M | 1.8M | |
| Net Debt | (86.7M) | (59.9M) | (41.3M) | (16.8M) | (15.1M) | (15.9M) | |
| Net Invested Capital | 99.2M | 65.5M | 38.5M | 14.9M | 13.4M | 12.7M | |
| Net Working Capital | 93.7M | 59.9M | 35.6M | 12.3M | 11.1M | 10.6M | |
| Capital Stock | 2.0M | 2.1M | 143.2M | 2.1M | 2.4M | 2.3M |
NuCana PLC Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 6.7M | 5.0M | 9.9M | 1.1M | 1.3M | 1.2M | |
| Operating Income | (36.4M) | (47.9M) | (39.1M) | (32.8M) | (29.5M) | (31.0M) | |
| Ebit | (29.5M) | (42.8M) | (52.9M) | (29.5M) | (26.5M) | (27.8M) | |
| Research Development | 25.9M | 36.8M | 36.4M | 25.1M | 28.8M | 22.1M | |
| Income Before Tax | (36.2M) | (47.8M) | (38.5M) | (32.0M) | (28.8M) | (30.3M) | |
| Net Income | (30.7M) | (40.5M) | (32.0M) | (27.6M) | (24.9M) | (26.1M) | |
| Income Tax Expense | (5.5M) | (7.3M) | (6.4M) | (4.4M) | (4.0M) | (4.2M) | |
| Tax Provision | (5.5M) | (7.3M) | (6.4M) | (4.4M) | (4.0M) | (4.2M) | |
| Interest Income | 246K | 103K | 669K | 754K | 867.1K | 584.6K | |
| Ebitda | (28.6M) | (41.9M) | (52.2M) | (28.9M) | (26.0M) | (27.3M) | |
| Net Interest Income | 246K | 103K | 669K | 754K | 867.1K | 601.8K |
NuCana PLC Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | (1.3M) | (3.6M) | 120K | 2.9M | 2.6M | 2.7M | |
| Change In Cash | 35.4M | (27.1M) | (18.4M) | (24.7M) | (22.2M) | (21.1M) | |
| Depreciation | 890K | 942K | 732K | 575K | 661.3K | 508.0K | |
| Capital Expenditures | 1.6M | 1.1M | 518K | 478K | 549.7K | 951.3K | |
| Net Income | (30.7M) | (40.5M) | (32.0M) | (27.6M) | (24.9M) | (26.1M) | |
| End Period Cash Flow | 87.4M | 60.3M | 41.9M | 17.2M | 19.8M | 18.8M | |
| Change To Netincome | (1.0M) | 6.2M | 11.7M | 4.4M | 5.1M | 3.8M | |
| Free Cash Flow | (23.3M) | (24.9M) | (23.7M) | (26.9M) | (24.2M) | (25.4M) | |
| Other Non Cash Items | 7.4M | 12.3M | 6.0M | 2.4M | 2.8M | 4.1M |
NuCana Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining NuCana PLC's current stock value. Our valuation model uses many indicators to compare NuCana PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NuCana PLC competition to find correlations between indicators driving NuCana PLC's intrinsic value. More Info.NuCana PLC is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, NuCana PLC's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the NuCana PLC's earnings, one of the primary drivers of an investment's value.NuCana PLC Systematic Risk
NuCana PLC's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. NuCana PLC volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-five with a total number of output elements of sixteen. The Beta measures systematic risk based on how returns on NuCana PLC correlated with the market. If Beta is less than 0 NuCana PLC generally moves in the opposite direction as compared to the market. If NuCana PLC Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one NuCana PLC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of NuCana PLC is generally in the same direction as the market. If Beta > 1 NuCana PLC moves generally in the same direction as, but more than the movement of the benchmark.
NuCana PLC Thematic Clasifications
NuCana PLC is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas
| Cancer Fighters | View |
Today, most investors in NuCana PLC Stock are looking for potential investment opportunities by analyzing not only static indicators but also various NuCana PLC's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of NuCana PLC growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
NuCana PLC January 31, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of NuCana PLC help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of NuCana PLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of NuCana PLC based on widely used predictive technical indicators. In general, we focus on analyzing NuCana Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build NuCana PLC's daily price indicators and compare them against related drivers.
| Information Ratio | (0.21) | |||
| Maximum Drawdown | 25.52 | |||
| Value At Risk | (7.21) | |||
| Potential Upside | 5.65 |
Complementary Tools for NuCana Stock analysis
When running NuCana PLC's price analysis, check to measure NuCana PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NuCana PLC is operating at the current time. Most of NuCana PLC's value examination focuses on studying past and present price action to predict the probability of NuCana PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NuCana PLC's price. Additionally, you may evaluate how the addition of NuCana PLC to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Stocks Directory Find actively traded stocks across global markets |